瑞格列奈在胰岛B细胞功能检测中的应用价值  

Repaglinide for the Beta-cell Function Testing

作　　者：罗宏斌[1] 冉燕雪[1] 陈小武[1] 林斌[1] 

机构地区：[1]广州医学院荔湾医院内分泌科,510170

出　　处：《中国糖尿病杂志》2002年第3期190-192,共3页Chinese Journal of Diabetes

摘　　要：目的　探讨瑞格列奈在胰岛 B细胞功能检测中的应用价值。　方法　对 31例 2型糖尿病患者先行常规口服葡萄糖耐量 -胰岛素释放试验 (OG- IRT,常规法 ) ,次日或第 3日在做 OG- IRT前加服 2 m g瑞格列奈片改良法。测定血清胰岛素并计算曲线下面积。　结果　瑞格列奈试验血清胰岛素水平及曲线下面积为 92 .2 1± 70 .6 9mu/ (h· L ) ,显著高于常规法 3.77± 34.91mu/ (h· L ) ,(P<0 .0 0 1) ;改良法胰岛素曲线下面积最少净增 2 9.6 3% ,最大增加 45 3.6 6 % ,中位数为 95 .2 4%。胰岛素曲线下面积增加值与 BMI呈正相关 ,与空腹血糖呈负相关。　结论　瑞格列奈试验比常规 OG- IRT能更好地反映胰岛 B细胞的储备功能。Objective To evaluate the role of Repaglinide on the B cell function in diabetics. Methods Oral glucose tolerance insulin release test (OG IRT) were performed firstly, and 2 or 3 days later 2 mg Repaglinide was taken orally (Repaglinide's test) before OG IRT was repeated in 31 type 2 diabetic subjects. The levels of serum glucose and insulin were measured, and the areas of insulin under the curve (AIUC) were calculated. Results The levels of insulin and the AIUC were higher in the Repaglinide's test than that in the OG IRT ( P<0.001 ). The increment of the AIUC between the OG IRT and Repaglinide's test was positively correlated with BMI and negatively with the levels of fasting plasma glucose. Conclusion Repaglinide OG IRT may reflect the reserved B cell function better than the routine OG IRT.

关 键 词：糖尿病 胰岛B细胞功能 瑞格列奈 应用 检测 

分 类 号：R587.104[医药卫生—内分泌]